Novartis to licence Akcea’s lipoprotein lowering drug
Novartis has announced that it is exercising its option to license the rights to develop and commercialise Akcea’s TQJ230.
Read More
Tag: TQJ230
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
